Dr. Ren received his AB in Biophysics from the University of California at Berkeley and his MD from the University of Chicago. He completed a pediatric residency and fellowship in allergy/immunology at Harvard Medical School, Children's Hospital in Boston and a second fellowship in pediatric pulmonology at St. Christopher's Hospital for Children in Philadelphia. He arrived in Rochester in 2001 to serve as the Chief of Pediatric Pulmonology and Co-Director Cystic Fibrosis Center and since been named, Director, Golisano Children's Hospital Outpatient Child Health Services.
Dr. Ren's research applies novel methods of pulmonary function testing in infants and young children to clinical and translational studies of pediatric respiratory disease.
Our current areas of disease focus are cystic fibrosis and premature lung
disease and Prematurity and Respiratory Outcomes Program (PROP).
Dr. Ren is the pulmonary PI and the co-chair of the Pulmonary Working Group for PROP. PROP is an NIH funded multicenter program whose aim is to promote collaborative, innovative research to identify mechanisms and associated functional and molecular biomarkers of respiratory disease risk of premature infants ready for discharge from the neonatal intensive care unit (NICU). As part of the PROP, he assist in conducting a longitudinal study of respiratory function in the first year of life utilizing non-invasive respiratory testing (including RIP) and performing infant PFTs using the raised volume rapidthoracoabdominal compression technique.
Epidemiologic Study of Cystic Fibrosis (ESCF)
The ESCF was a prospective observational study of CF patients in North America. Data were collected from 1994-2005, and analyses are still ongoing. Using ESCF data, we have studied the effect of inhaled corticosteroid therapy on lung function, the impact of methicillin resistant S. aureus infection on lung function, and the relationship between infant care patterns and outcomes. We recently used ESCF data to demonstrate that wheezing in early childhood is associated with lower lung function in children with CF.
Early Pseudomonas Infection Control Observational Study (EPIC)
EPIC is a longitudinal cohort study of young CF patients whose primary goal is to identify risk factors for the acquisition of Pseudomonas aeruginosa (Pa). Secondary objectives include better definition of outcomes associated with Pa infection and the impact of other organisms on clinical outcomes.
CF Clinical Trials
As a member of the CF Foundation Therapeutics Development Network the Pediatric Pulmonary Division is involved in a number of clinical trials. Further information regarding clinical trials can be found at the Division of Pediatric Pulmonology website: http://www.urmc.rochester.edu/pediatrics/research/subspecialty/pulmonology
Advanced Lung Function Testing
Multiple breath washout (MBW) equipment was recently added to our Pediatric Pulmonary Function Laboratory. MBW is a noninvasive method to assess ventilation inhomogeneity, a feature of many pediatric lung diseases, such as CF. Our group is presently developing pilot projects to apply MBW to the study of CF and preterm lung disease.